---
schema_version: "secwatch.filing_event.v1"
accession: "0001798749-23-000037"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:25:27.178756+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aerovate Therapeutics Q1 net loss $16.5M; Phase 2b topline data pushed to Q2 2024

## Summary
- Topline Phase 2b data from IMPAHCT trial of AV-101 now expected in Q2 2024; >100 sites in 20 countries.
- Cash, equivalents and short-term investments $118.9M at March 31, 2023; runway into H2 2025.
- Net loss $16.5M for Q1 2023 vs $10.9M Q1 2022; R&D expenses $13.5M (up from $7.3M).
- Enrollment pace increasing but slower than expected due to post-COVID factors.

## SEC filing metadata
- accession: 0001798749-23-000037
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000037/0001798749-23-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000037/tmb-20230515x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001798749-23-000037
- JSON: https://secwatch.observer/filing/0001798749-23-000037.json
- Plain text: https://secwatch.observer/filing/0001798749-23-000037.txt

## Key facts
- Earnings Releases
  Jade Biosciences, Inc. reported first quarter 2023 results: net income -$16.5 million.
  - Period: first quarter 2023
  - Net income: -$16.5 million
  - Result: reported results
  source text: Net loss for the first quarter ended March 31, 2023 was $16.5 million as compared to $10.9 million for the first quarter ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000037/0001798749-23-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.